News
BPMC
84.10
-2.84%
-2.46
Weekly Report: what happened at BPMC last week (0902-0906)?
Weekly Report · 3d ago
Even though Blueprint Medicines (NASDAQ:BPMC) has lost US$577m market cap in last 7 days, shareholders are still up 62% over 1 year
Simply Wall St · 5d ago
Blueprint Medicines Enters Oversold Territory (BPMC)
NASDAQ · 6d ago
Weekly Report: what happened at BPMC last week (0826-0830)?
Weekly Report · 09/02 09:28
Weekly Report: what happened at BPMC last week (0819-0823)?
Weekly Report · 08/26 09:27
Weekly Report: what happened at BPMC last week (0812-0816)?
Weekly Report · 08/19 09:25
Is Blueprint Medicines (NASDAQ:BPMC) Using Too Much Debt?
Simply Wall St · 08/16 11:00
Weekly Report: what happened at BPMC last week (0805-0809)?
Weekly Report · 08/12 09:25
Blueprint Medicines Breaks Below 200-Day Moving Average - Notable for BPMC
NASDAQ · 08/08 15:52
DaVita (DVA) Q2 Earnings & Revenues Top Estimates, Margins Up
NASDAQ · 08/07 16:55
Masimo (MASI) Q2 Earnings Beat Estimates, Gross Margin Up
NASDAQ · 08/07 16:53
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Blueprint Medicines (BPMC), Adaptimmune Therapeutics (ADAP) and Ardelyx (ARDX)
TipRanks · 08/07 05:54
Blueprint Medicines Is Maintained at Buy by Needham
Dow Jones · 08/05 19:23
Blueprint Medicines Price Target Raised to $133.00/Share From $130.00 by Needham
Dow Jones · 08/05 19:23
Needham Maintains Buy on Blueprint Medicines, Raises Price Target to $133
Benzinga · 08/05 19:13
TD Cowen Sticks to Their Buy Rating for Blueprint Medicines (BPMC)
TipRanks · 08/05 11:17
Weekly Report: what happened at BPMC last week (0729-0802)?
Weekly Report · 08/05 09:28
Blueprint Medicines (BPMC) Receives a Hold from Barclays
TipRanks · 08/05 07:46
Blueprint Medicines Is Maintained at Buy by Guggenheim
Dow Jones · 08/02 19:19
Blueprint Medicines Price Target Raised to $138.00/Share From $130.00 by Guggenheim
Dow Jones · 08/02 19:19
More
Webull provides a variety of real-time BPMC stock news. You can receive the latest news about Blueprint Medicines Corp through multiple platforms. This information may help you make smarter investment decisions.
About BPMC
Blueprint Medicines Corporation is a global precision therapy company that is inventing life-changing medicines in two areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib), to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include Elenestinib (BLU-263) (KIT), AYVAKIT (avapritinib) (KIT), Wild-type KIT research program, GAVRETO (pralsetinib) (RET), BLU-945 (EGFR), BLU-525 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2), AYVAKIT (PDGFRA), GAVRETO (RET), BLU-222 (CDK2) and BLU-852 (MAP4K1). It is developing elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders.